Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $66.00

Rapport Therapeutics (NASDAQ:RAPP) had its price objective increased by stock analysts at HC Wainwright from $40.00 to $66.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 38.22% from the stock’s previous close. HC Wainwright also issued estimates for Rapport Therapeutics’ Q3 2026 earnings at ($1.36) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($4.51) EPS, FY2027 earnings at ($6.80) EPS, FY2028 earnings at ($8.40) EPS, FY2029 earnings at ($8.08) EPS and FY2030 earnings at ($6.96) EPS.

Other equities analysts also recently issued reports about the stock. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Leerink Partners assumed coverage on Rapport Therapeutics in a report on Wednesday, June 24th. They set an “outperform” rating and a $52.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $65.00 target price on shares of Rapport Therapeutics in a report on Wednesday, August 5th. William Blair began coverage on Rapport Therapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating for the company. Finally, Wall Street Zen downgraded Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.57.

Rapport Therapeutics Stock Down 2.2%

Shares of NASDAQ:RAPP traded down $1.07 during trading on Wednesday, reaching $47.75. 125,066 shares of the company traded hands, compared to its average volume of 348,491. The firm has a market cap of $2.29 billion, a P/E ratio of -15.71 and a beta of 0.97. Rapport Therapeutics has a 1-year low of $13.86 and a 1-year high of $49.50. The firm has a fifty day simple moving average of $40.25 and a 200 day simple moving average of $34.91.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, research analysts anticipate that Rapport Therapeutics will post -4.09 EPS for the current year.

Insider Buying and Selling

In related news, CEO Abraham Ceesay sold 2,210 shares of the firm’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $42.11, for a total value of $93,063.10. Following the completion of the transaction, the chief executive officer directly owned 537,607 shares of the company’s stock, valued at $22,638,630.77. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of Rapport Therapeutics stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $40.05, for a total transaction of $743,808.60. Following the sale, the insider owned 6,280,525 shares in the company, valued at $251,535,026.25. This represents a 0.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 12.48% of the stock is currently owned by company insiders.

Institutional Trading of Rapport Therapeutics

Several institutional investors have recently made changes to their positions in RAPP. KBC Group NV bought a new stake in Rapport Therapeutics in the first quarter valued at about $30,000. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics during the fourth quarter valued at approximately $37,000. Russell Investments Group Ltd. bought a new stake in shares of Rapport Therapeutics in the 3rd quarter valued at approximately $43,000. State of Wyoming acquired a new position in shares of Rapport Therapeutics in the 2nd quarter worth approximately $65,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Rapport Therapeutics by 64.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after buying an additional 905 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.